Current Treatment Landscape for Second and Subsequent Lines of Therapy in Metastatic Urothelial Carcinoma

Use this web-based tool to see recommendations from 5 experts on treating patients with bladder cancer.

Matthew Galsky, MD Shilpa Gupta, MD Matthew I. Milowsky, MD Elizabeth R. Plimack, MD, MS Arlene O. Siefker-Radtke, MD Released: July 19, 2021

On-demand webcast on PARP inhibitor combination therapies in prostate cancer featuring 3 faculty experts presented by Clinical Care Options (CCO)

Charles J. Ryan, MD
Program Director Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: July 7, 2021 Expired: July 6, 2022

Dr. Charles J. Ryan discusses the rationale and evidence for PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: July 2, 2021

Downloadable PDF with highlights from a CCO podcast on PARP inhibitors and emerging combination strategies in prostate cancer.

Charles J. Ryan, MD
Program Director Wassim Abida, MD, PhD Joaquin Mateo, MD, PhD Released: June 30, 2021